LCD-L36044
Document details
Summary
The recent LCD from Palmetto GBA affects billing for genetic testing related to BCR-ABL Negative Myeloproliferative Disease. Providers must ensure compliance with the updated guidelines to avoid claimNew guidelines impact billing for genetic tests in myeloproliferative disease.
Affected codes
ICD-10-CM
Affected specialty
Hematology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36044&ver=59CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA206769 · Hematology
Argatroban in 0.9% Sodium Chloride (NDA206769) is a new intravenous formulation of the established direct thrombin inhibitor argatroban, approved via a Type 5 submission by Teva Pharmaceuticals. As an
View alertPolicy FDA-BLA761113 · Hematology
Sarclisa (isatuximab) is an injectable CD38-directed cytolytic antibody approved for multiple myeloma, administered via intravenous injection and billing under Medicare Part B. As a hospital or office
View alertPolicy FDA-BLA761166 · Hematology
Besremi (ropeginterferon alfa-2b) is a subcutaneously administered injectable approved for polycythemia vera, supporting a Part B billing pathway as a physician-administered drug. As an orphan drug in
View alertPolicy FDA-NDA209552 · Hematology
The recent FDA approval of Argatroban as an injectable drug suggests it will likely be assigned a J-code for billing under Medicare Part B. Since it is an anticoagulant, providers may receive pass-thr
View alert